Does Creatine Help Women During Menopause?

Why the claim is plausible

Creatine supports the rapid recycling of energy in muscle. If it helps someone perform or adapt to repeated resistance exercise, it could contribute to preserving strength during a life stage when muscle and bone concerns become more prominent. That is a reasonable rationale for research.

It is still important to distinguish evidence in men, mixed older-adult groups and women whose menopause status is actually documented. This investigation focuses on the last group, rather than repeating our general creatine and ageing articles.

The direct 2026 review

A menopause-specific systematic review included seven randomised trials with 608 women overall. Five trials with 338 participants contributed to the lean-mass analysis: the average additional difference favoured creatine by 0.37 kg, with a 95% confidence interval from 0.05 to 0.69 kg. Three trials with 111 participants found an average leg-press one-repetition-maximum advantage of 7.5 kg, with substantial uncertainty around that estimate. [1]

Benefits were most apparent in studies combining creatine with resistance training. Most trials had some risk-of-bias concerns, and the review was not prospectively registered. Different doses and training programmes make it difficult to prescribe one universal expectation. [1]

These are modest group averages, not a promise of a particular body transformation. Lean mass measured by DXA includes water and other tissue; the strength findings add useful functional context, but neither tells us that every woman will respond identically.

The long bone-health trial

In a two-year trial, 237 postmenopausal women were randomised to creatine or placebo while undertaking resistance training and walking. Creatine did not improve the primary femoral-neck bone-density outcome, nor produce an additional density benefit at the total hip or lumbar spine. Some secondary bone-geometry measures were more favourable. [2]

The trial also reported a lean-tissue benefit in a valid-completer subanalysis. That is narrower than a clear benefit in every randomised participant, particularly with imperfect adherence. Bone geometry and lean tissue are also different from demonstrated fracture prevention. [2]

A separate two-year study of 200 postmenopausal women with osteopenia used 3 g/day without a structured resistance-training intervention. It did not improve bone outcomes, lean mass or muscle function. This helps explain why creatine should not be presented as a replacement for exercise. [3]

What about perimenopause, brain fog and symptoms?

A small trial in 36 peri- or menopausal women investigated low-dose creatine hydrochloride, alone or in combination with creatine ethyl ester, over eight weeks. It reported selected cognitive, brain-creatine and biochemical findings. This is an early formulation-specific study, not confirmation that ordinary creatine monohydrate treats brain fog, hot flushes or the full range of menopause symptoms. [4]

Small groups, multiple outcomes and alternative formulations mean replication matters. The muscle meta-analysis should not be used to validate unrelated symptom claims. Nor should a cognition signal be treated as evidence of reduced fracture risk.

How to interpret a meaningful benefit

Training itself matters greatly. The relevant creatine effect is the additional difference over the same programme with placebo, not the total improvement in the creatine group. A trial in which both groups become stronger does not attribute all their progress to the supplement.

Similarly, the absence of a consistent bone-density effect does not invalidate a muscle benefit. The useful conclusion is outcome-specific: a potentially worthwhile adjunct for training, with much weaker justification as a comprehensive menopause remedy.

Safety and remaining uncertainties

In the menopause-specific review, adverse events were generally mild and similar to placebo, with no change in the reported renal indices. Trials were nevertheless selective and cannot establish safety for every medical condition or uncommon long-term event. [1]

People with kidney disease, relevant medicines or complex medical needs should discuss supplementation with their clinician. Creatine can affect serum creatinine, so tell the clinician if you use it when interpreting kidney tests. [5] Evidence does not require a more expensive creatine form to obtain the established muscle rationale; the largest evidence base concerns monohydrate.

What this means for you

If your goal is strength, make progressive resistance exercise the foundation, supported by adequate nutrition. Creatine monohydrate can be considered as an optional adjunct with realistic expectations, rather than a requirement for navigating menopause.

For osteoporosis risk or troublesome menopause symptoms, use an appropriate assessment and established care. A supplement's muscle evidence is not a substitute for those separate decisions.

Research & Sources

Evidence reviewed: October 2026

Evidence vs Hype explains scientific research for educational purposes and does not provide individual medical diagnosis or treatment.